Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

被引：1

作者：

Lavie, David ^{[1
]}

Timmerman, John ^{[2
]}

Garcia-Sanz, Ramon ^{[3
]}

Kim, Won Seog ^{[4
]}

Kim, Tae Min ^{[5
]}

Avigdor, Abraham ^{[6
]}

Dierickx, Daan ^{[7
]}

Jagadeesh, Deepa ^{[8
]}

Molin, Daniel L. ^{[9
]}

Ozcan, Muhit ^{[10
]}

Sevindik, Omur Gokmen ^{[11
]}

Saeed, Hayder ^{[12
]}

Sidi, Yulia ^{[13
]}

Pillai, Pallavi ^{[13
]}

Marinello, Patricia ^{[13
]}

Herrera, Alex F. ^{[14
]}

机构：

[1] Hadassah Med Ctr, Jerusalem, Israel

[2] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA

[3] Univ Hosp Salamanca, Salamanca, Spain

[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[5] Seoul Natl Univ Hosp, Seoul, South Korea

[6] Sheba Med Ctr Tel HaShomer, Ramat Gan, Israel

[7] Univ Hosp Leuven, Leuven, Belgium

[8] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA

[9] Uppsala Univ, Uppsala, Sweden

[10] Ankara Univ, Sch Med, Hematol Dept, Ankara, Turkiye

[11] Istanbul Medipol Univ, Int Sch Med, Istanbul, Turkiye

[12] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[13] Merck & Co Inc, Rahway, NJ 07065 USA

[14] City Hope Natl Med Ctr, Duarte, CA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-182119

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[31] AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial
Sasse, Stephanie
Momotow, Jesko
Plutschow, Annette
Huttmann, Andreas
Basara, Nadezda
Koenecke, Christian
Martin, Sonja
Bentz, Martin
Grosse-Thie, Christina
Thorspecken, Sven
de Wit, Maike
Kobe, Carsten
Dietlein, Markus
von Tresckow, Bastian
Fuchs, Michael
Borchmann, Peter
Engert, Andreas
BLOOD, 2020, 136
[32] AFM13 in patients with relapsed or refractory Hodgkin Lymphoma: Final results of an open-label, randomized, multicenter phase II trial
Momotow, J.
Sasse, S.
Pluetschow, A.
Huettmann, A.
Basara, N.
Koenecke, C.
Martin, S.
Bentz, M.
Grosse-Thie, C.
Thorspecken, S.
de Wit, M.
Kobe, C.
Dietlein, M.
von Tresckow, B.
Fuchs, M.
Borchmann, P.
Engert, A.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 89 - 89
[33] Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
Moskowitz, Alison J.
Shah, Gunjan
Schoder, Heiko
Ganesan, Nivetha
Hancock, Helen
Davey, Theresa
Sohail, Samia
Santarosa, Alayna
Pomerantz, Lauren
Jarjies, Christine
Galasso, Natasha
Neuman, Rachel
Kumar, Anita
Lahoud, Oscar B.
Batlevi, Connie Lee
Hamlin, Paul A.
Straus, David J.
Rodriguez-Rivera, Ildefonso
Owens, Colette
Caron, Philip
Intlekofer, Andrew M.
Hamilton, Audrey
Horwitz, Steven M.
Falchi, Lorenzo
Joffe, Erel
Palomba, Maria Lia
Noy, Ariela
Matasar, Matthew J.
Pongas, Georgios
Vardhana, Santosha
von Keudell, Gottfried R.
Yahalom, Joachim
Zelenetz, Andrew D.
Moskowitz, Craig H.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 14 - 15
[34] Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
Moskowitz, Alison J.
Shah, Gunjan
Schoder, Heiko
Ganesan, Nivetha
Hancock, Helen
Davey, Theresa
Sohail, Samia
Santarosa, Alayna
Pomerantz, Lauren
Jarjies, Christine
Galasso, Natasha
Neuman, Rachel
Kumar, Anita
Lahoud, Oscar B.
Batlevi, Connie Lee
Hamlin, Paul A.
Straus, David J.
Rodriguez-Rivera, Ildefonso
Owens, Colette
Caron, Philip
Intlekofer, Andrew M.
Hamilton, Audrey
Horwitz, Steven M.
Falchi, Lorenzo
Joffe, Erel
Palomba, Maria Lia
Noy, Ariela
Matasar, Matthew J.
Pongas, Georgios
Vardhana, Santosha
von Keudell, Gottfried R.
Yahalom, Joachim
Zelenetz, Andrew D.
Moskowitz, Craig H.
BLOOD, 2020, 136
[35] Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM).
Van Droogenbroeck, Jan
Vlummens, Philip
Lavi, Noa
Wu, Ka Lung
Fu, Jiayu
Feng, Huaibao
Carson, Robin L.
Crist, Wendy
Schecter, Jordan
Cohen, Yael
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[36] Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers
Rossi, Cedric
Gilhodes, Julia
Maerevoet, Marie
Herbaux, Charles
Morschhauser, Franck
Brice, Pauline
Garciaz, Sylvain
Borel, Cecile
Ysebaert, Loic
Oberic, Lucie
Lazarovici, Julien
Deau, Benedicte
Dupuis, Jehan
Chauchet, Adrien
Abraham, Julie
Bijou, Fontanet
Stamatoullas-Bastard, Aspasia
Malfuson, Jean-Valere
Golfier, Camille
Laurent, Camille
Pericart, Sarah
Traverse-Glehen, Alexandra
Kanoun, Salim
Filleron, Thomas
Casasnovas, Rene-Olivier
Ghesquieres, Herve
AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (08) : 1042 - 1049
[37] Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
Carlo-Stella, Carmelo
Ansell, Stephen
Zinzani, Pier Luigi
Radford, John
Maddocks, Kami
Pinto, Antonio
Collins, Graham P.
Bachanova, Veronika
Bartlett, Nancy
Bence-Bruckler, Isabelle
Hamadani, Mehdi
Kline, Justin
Mayer, Jiri
Savage, Kerry J.
Advani, Ranjana
Caimi, Paolo
Casasnovas, Rene-Olivier
Feldman, Tatyana
Hess, Brian
Bastos-Oreiro, Mariana
Iyengar, Sunil
Eisen, Sandy
Negievich, Yanina
Wang, Luqiang
Wuerthner, Jens
Herrera, Alex F.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S347 - S347
[38] Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
Dreyling, Martin
Jurczak, Wojciech
Jerkeman, Mats
Silva, Rodrigo Santucci
Rusconi, Chiara
Trneny, Marek
Offner, Fritz
Caballero, Dolores
Joao, Cristina
Witzens-Harig, Mathias
Hess, Georg
Bence-Bruckler, Isabelle
Cho, Seok-Goo
Bothos, John
Goldberg, Jenna D.
Enny, Christopher
Traina, Shana
Balasubramanian, Sriram
Bandyopadhyay, Nibedita
Sun, Steven
Vermeulen, Jessica
Rizo, Aleksandra
Rule, Simon
LANCET, 2016, 387 (10020): : 770 - 778
[39] Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment
Drees, Esther E. E.
Jauw, Yvonne W. S.
van Dijk, Erik
Borchmann, Sven
Verkuijlen, Sandra A. W. M.
Stathi, Phylicia
Groenewegen, Nils J.
Hijmering, Nathalie J.
Berry, Daniella R. A. I.
Meershoek, Eric J.
Hoogmoed, Danielle
Kwakman, Anne
Molenaar, Tessa J.
Pegtel, Dirk M.
Ylstra, Bauke
de Jong, Daphne
Zijlstra, Josee M.
Roemer, Margaretha G. M.
HEMASPHERE, 2022, 6 (07):
[40] KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma
Mateos, M. V.
Blacklock, H.
Rocafiguera, A. O.
Iida, S.
Jagannath, S.
Lonial, S.
Kher, U.
Farooqui, M.
Marinello, P.
San-Miguel, J.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →